Non-alcoholic fatty liver disease and clinical outcomes in
patients with COVID-19: A comprehensive systematic review and
meta-analysis

J 2021

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

SINGH, A., Mohammad Salman HUSSAIN a B. ANTONY

Základní údaje

Originální název

Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis

Autoři

SINGH, A. (garant), Mohammad Salman HUSSAIN (356 Indie, domácí) a B. ANTONY

Vydání

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, OXFORD, ELSEVIER SCI LTD, 2021, 1871-4021

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/21:00122062

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.dsx.2021.03.019

UT WoS

000661873400025

Klíčová slova anglicky

NAFLD; COVID-19; Mortality; Severity; Systematic review

Štítky

14119612, 14119613, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 9. 8. 2021 13:08, Mgr. Tereza Miškechová

Anotace

V originále

Background: Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized. Objectives: To systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19. Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model. Results: Fourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24-3.02; p < 0.001) (studies,n:8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI:1.26-2.20; p < 0.001) (studies,n:2), and aOR for mortality for was 1.01 (95%CI:0.65-1.58; p 1/4 0.96) (studies,n:2). Conclusions: An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Citovat

SINGH, A., Mohammad Salman HUSSAIN a B. ANTONY. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS. OXFORD: ELSEVIER SCI LTD, 2021, roč. 15, č. 3, s. 813-822. ISSN 1871-4021. Dostupné z: https://dx.doi.org/10.1016/j.dsx.2021.03.019.

@article{1785582,
   author = {Singh, A. and Hussain, Mohammad Salman and Antony, B.},
   article_location = {OXFORD},
   article_number = {3},
   doi = {http://dx.doi.org/10.1016/j.dsx.2021.03.019},
   keywords = {NAFLD; COVID-19; Mortality; Severity; Systematic review},
   language = {eng},
   issn = {1871-4021},
   journal = {DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS},
   title = {Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis},
   url = {https://www.sciencedirect.com/science/article/pii/S187140212100093X?via%3Dihub},
   volume = {15},
   year = {2021}
}

TY  - JOUR
ID  - 1785582
AU  - Singh, A. - Hussain, Mohammad Salman - Antony, B.
PY  - 2021
TI  - Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis
JF  - DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
VL  - 15
IS  - 3
SP  - 813-822
EP  - 813-822
PB  - ELSEVIER SCI LTD
SN  - 18714021
KW  - NAFLD
KW  - COVID-19
KW  - Mortality
KW  - Severity
KW  - Systematic review
UR  - https://www.sciencedirect.com/science/article/pii/S187140212100093X?via%3Dihub
N2  - Background: Non-alcoholic fatty liver disease (NAFLD) patients represent a vulnerable population that may be susceptible to more severe COVID-19. Moreover, not only the underlying NAFLD may influence the progression of COVID-19, but the COVID-19 may affect the clinical course of NAFLD as well. However, comprehensive evidence on clinical outcomes in patients with NAFLD is not well characterized. Objectives: To systematically review and meta-analysis the evidence on clinical outcomes in NAFLD patients with COVID-19. Methods: MEDLINE, EMBASE, and Cochrane Central were searched from inception through November 2020. Epidemiological studies assessing the clinical outcomes in COVID-19 patients with NAFLD were included. Newcastle-Ottawa Scale (NOS) was used to assess study quality. Generic inverse variance method using RevMan was used to determine the pooled estimates using the random-effects model. Results: Fourteen studies consisting of 1851 NAFLD patients, were included. Significant heterogeneity was observed among the studies, and studies were of moderate to high quality [mean, (range):8 (6, 8)]. For NAFLD patients, the adjusted odds ratio (aOR) for the severe COVID-19 was 2.60 (95%CI:2.24-3.02; p < 0.001) (studies,n:8), aOR for admission to ICU due to COVID-19 was 1.66 (95%CI:1.26-2.20; p < 0.001) (studies,n:2), and aOR for mortality for was 1.01 (95%CI:0.65-1.58; p 1/4 0.96) (studies,n:2). Conclusions: An increased risk of severe COVID-19 infection and admission to ICU due to COVID-19 with no difference in mortality was observed between NAFLD and non-NAFLD patients. Future studies should include the mortality outcome to conclusively elucidate the impact of NAFLD in patients with COVID-19. (C) 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.
ER  -

SINGH, A., Mohammad Salman HUSSAIN a B. ANTONY. Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: A comprehensive systematic review and meta-analysis. \textit{DIABETES \&{} METABOLIC SYNDROME-CLINICAL RESEARCH \&{} REVIEWS}. OXFORD: ELSEVIER SCI LTD, 2021, roč.~15, č.~3, s.~813-822. ISSN~1871-4021. Dostupné z: https://dx.doi.org/10.1016/j.dsx.2021.03.019.

Podrobný výpis o publikaci